Longterm Efficacy and Safety of NVP-Based HAART in HIV-1 Positive Patients in the Daily Clinical Practice.

Trial Profile

Longterm Efficacy and Safety of NVP-Based HAART in HIV-1 Positive Patients in the Daily Clinical Practice.

Completed
Phase of Trial: Phase IV

Latest Information Update: 05 May 2014

At a glance

  • Drugs Nevirapine (Primary) ; Antiretrovirals
  • Indications HIV-1 infections
  • Focus Adverse reactions
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 21 Sep 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 23 Aug 2011 Planned end date changed from Jul 2011 to Sep 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top